Back to trials
completed
Not Applicable

NCT04218708

Electronic Cigarettes as a Harm Reduction Strategy Among People Living With HIV/AIDS

Sponsored by NYU Langone Health

Summary

This is a research study to understand and determine the effectiveness of electronic cigarettes versus nicotine replacement therapy in adults who smoke and also live with HIV/AIDS in effort to reduce cigarette smoking.

Eligibility Criteria

Inclusion Criteria: * Current Combustible Cigarette (CC) smokers (more than 5 packs in a lifetime; smokes 4 or more days/week), * Smokes at least 10 cigarettes per day on days they smoke CC. * Motivated to quit smoking (at least a 5 on a 10-point Likert scale). * Must be able to provide consent * Agree to be randomized and followed-up with, * Reside in New York City * Be willing to use an e-cigarette or NRT for 12 weeks. Exclusion Criteria: * Are pregnant (as determined by urine test) or breastfeeding (self-reported), * State diagnosis of any medical condition (angina/heart disease) precluding use of nicotine patch or gum, or by self-report in screening questionnaire * Reporting using NRTs or e-cigarettes or within the last 30 days * Have untreated/are undergoing current treatment for psychiatric illness or cognitive impairment at time of initial screening as determined by the subjects' primary care doctor or a licensed study team member in screening * Report a history of severe or untreated cardiopulmonary disease such as asthma or emphysema.

Locations (1)

NYU Langone Health

New York, New York, United States

Why you can trust this information
Registry sourcesclinicaltrials_gov
Source last updated12/20/2024
Clintriva indexed9/27/2026, 9:21:09 PM
Registry records1
Relationships needing review0

Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.

Interested in this trial?

Express your interest and we'll connect you with the trial team.

Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.

Quick Facts
Start DateJun 17, 2021
CompletionDec 15, 2023
Enrollment0/64
CountryUnited States

Conditions

Nicotine Addiction
View on registry
Clintriva
GDPR Controls Mapped HIPAA Safeguards Mapped NHS DSP Controls Mapped SOC 2 Controls Mapped

© 2026 Clintriva. All rights reserved.